Molecular Model of the αIIbβ3 Integrin

Journal of Medicinal Chemistry

Volumn 46, Issue 25, 2003, Pages 5316-5325

  Feuston, Bradley P ^a   Culberson, J Christopher ^a   Hartman, George D ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA3BBETA3 INTEGRIN; INTEGRIN; PROTEIN INHIBITOR; PROTEIN SUBUNIT; SB 273005; SULFONAMIDE; TIROFIBAN; UNCLASSIFIED DRUG;

ARTICLE; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TARGETING; HUMAN; HYDROGEN BOND; LIGAND BINDING; MOLECULAR INTERACTION; MOLECULAR MODEL; MUTAGENESIS; NUCLEOTIDE SEQUENCE; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN STRUCTURE; PROTEIN TARGETING; SEQUENCE HOMOLOGY;

AMINO ACID SEQUENCE; BINDING SITES; LIGANDS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PIPERIDINES; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROTEIN BINDING; PYRIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 0344550400     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030146j     Document Type: Article

References (28)

1. Curley, G. P.; Blum, H.; Humphries, M. J. Integrin antagonists. Cell Mol. Life Sci. 1999, 56, 427-441.
2. Coller, B. S. Perspective Series: Cell adhesion in vascular biology. J. Clin. Invest. 1997, 99, 1467-1471.
3. Scarborough, R. M.; Gretler, D. D. Platelet Glycoprotein IIb-IIIa Antagonists as Prototypical Integrin Blockers: Novel Parenteral and Potential Oral Antithrombotic Agents. J. Med. Chem. 2000, 43, 3453-3473.
4. Duong, L. T.; Rodan, G. A. Regulation of osteoclast formation and function. Rev. Endo. Metab. Dis. 2001, 2, 95-104
5. Humphries, M. J. Integrin Structure. Biochem. Soc. Trans. 2002, 28, 311-339.
6. Adair, B. D.; Yeager, M. Three-dimensional Model of the human platelet integrin αIIbβ3 based upon electron cryomicroscopy and X-ray crystallography. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 14059-14064.
7. Lee, J. O.; Rieu, P.; Arnaout, M. A.; Liddington, R. Crystal structure of the A domain from the alpha subunit of integrin CR3 (CD11b/CD18). Cell 1995, 80, 631-638.
8. Michishita, M.; Videm, V.; Arnaout, M. A. A novel divalent cation-binding site in the A domain of the beta 2 integrin CR3 (CD11b/CD18) is essential for ligand binding. Cell 1993, 72, 857-867.
9. Loftus, J. C.; O'Toole, T. E.; Plow, E. F.; Glass, A.; Frelinger, A. L., III; Ginsberg, M. H. A beta 3 integrin mutation abolishes ligand binding and alters divalent cation-dependent conformation. Science 1990, 249, 915-918.
10. PDB ID: 1JV2. Xiong, J.-P.; Stehe, T.; Diefenbach, B.; Zhang, R.; Dunker, R.; Scott, D. L.; Joachimiak, A.; Goodman, S. L.; Arnaout, M. A. Crystal Structure of the Extracellular Segment of Integrin αVβ3. Science 2001, 294, 339-345.
11. Pfaff, M.; Tangemann, K.; Muller, B.; Gurrath, M.; Muller, G.; Kessler, H.; Timpl, R.; Engel, J. Selective Recognition of Cyclic RGD Peptides of NMR Defined Conformation by αIIbβ3, αVβ3, and α5β1 Integrins. J. Biol. Chem. 1994, 269, 20233-20238.
12. Hartman, G. D.; Egbertson, M. S.; Halczenko, W.; Laswell, W.; Duggan, M. E.; Smith, R. L.; Naylor, A. M.; Manno, P. D.; Lynch, R. J.; Zhang, G.; Chang, C. T.-C.; Gould, R. L. Nonpeptide Fibrinogen Receptor Antagonists. 1. Discovery And Design of Exosite Inhibitors. J. Med. Chem. 1992, 35, 4640-4642.
13. Askew, B. C.; Bednar, R. A.; Bednar, B.; Claremon, D. A.; Cook, J. J.; McIntyre, C. J.; Hunt, C. A.; Gould, R. J.; Lynch, R. J.; Lynch, J. J.; Gaul, S. L.; Stranieri, M. T.; Sitko, G. R.; Holahan, M. A.; Glass, J. D.; Hamill, T.; Gorham, L. M.; Prueksaritanont, T.; Baldwin, J. J.; Hartman, G. D. Non-Peptide Glycoprotein IIb/IIIa INhibitors. 17. Design And Synthesis Of Orally Active, Long-acting Non-peptide Fibrinogen Receptor Antagonists. J. Med. Chem. 1997, 40, 1779-1788.
14. Hartman, G. D.; Duggan, M. E.; Hoffman, W. F.; Meissner, R. S.; Perkins, J. J.; Zartman, A. E.; Naylor-Olsen, A.; Cook, J. J.; Glass, J.; Lynch, R. J.; Zhang, G.; Gould, R. Nonpeptide Glycoprotein IIB/IIIA Inhibitors. 19. A new Design papradigm employing linearly minimized, centrally constrained, exosite inhibitors. Bioorg. Med. Chem. Lett. 1999, 9, 863-868.
15. 3 integrin. J. Med. Chem. 2002, 45, 5640-5648.
16. 3 Antagonist. J. Med. Chem. 2000, 43, 3736-3745.
17. 3 Antagonist. 2. Constrained Glycyl Amides Derived From RGD Tripeptide. Bioorg. Med. Chem. Lett. 2002, 12, 25-29.
18. 3 Antagonists. Part III: Identification of Potent RGD Mimetics Incorporating Novel β-Amino Acids as Aspartic Acid Replacements. Bioorg. Med. Chem. Lett. 2002, 12, 31-34
19. Duggan, M. E. Preparation of heterocyclic peptide derivatives as integrin antagonists. PCT Int. Appl.; Merck & Co., Inc.: USA, 1998; p 74.
20. 3 Antagonists. Part 4: Potent and Orally Bioavailable Chain Shortened RGD Mimietics. Bioorg. Med. Chem. Lett. 2002, 12, 2463-2465.
21. PDB ID: 1JX5. Kamata, T.; Tieu, K. K.; Irie, A.; Springer, T. A.; Takada, Y. Amino acid residues in the alpha(IIb) subunit that are critical for ligand binding to integrin alpha(IIb)beta(3) are clustered in the beta-propeller model. J. Biol. Chem. 2001, 276, 44275-44283.
22. Chemical Computing Group, v.2000.02, 1010 Sherbrooke Street West, Suite 910, Montreal, Quebec, Canada H3A 2R7.
23. BatchMin and MacroModel were developed in the laboratories of Professor Clark Still (Columbia University) and are available from Schrodinger, Inc. (Portland, OR). Version 5.0 was released in 1995.
24. Halgren, T. A. Merck Molecular Force Field. I Basis, Form, Scope, Parameterization, and Performance of MMFF94. J. Comp Chem. 1996, 17, 490-519.
25. Yamamoto, M.; Fisher, J. E.; Gentile, M.; Seedor, J. G.; Leu, C.-T.; Rodan, S. B.; Rodan, G. A. The integrin ligand echistatin prevents bone loss in ovariectomized mice and rats. Endocrinology 1998, 139, 1411-1419.
26. 3 (Vitronectin Receptor) Antagonist, in Rat Adjuvant-Induced Arthritis. Arthritis Rheum. 2001, 44, 128-137.
27. Feuston, B. P.; Miller, M. D.; Culberson, J. C.; Nachbar, R. B.; Kearsley, S. K. Comparison of Knowledge-Based and Distance Geometry Approaches for Generation of Molecular Conformations. J. Chem. Inf. Comput. Sci. 2001, 41, 754-763.
28. Hunter, C. A.; Sanders, J. K. M. The Nature of π-π Interactions. J. Am. Chem. Soc. 1990, 112, 5525-5534.